Literature DB >> 1531719

Persistence of antibody to hepatitis B surface antigen after low-dose, intradermal hepatitis B immunization and response to a booster dose.

J P Bryan1, M H Sjogren, P Macarthy, E Cox, L J Legters, P L Perine.   

Abstract

To determine the duration of antibody after low-dose, intradermal (i.d.), plasma-derived hepatitis B vaccination and the response to a booster dose, we studied two classes of medical students who were immunized with 2 micrograms doses i.d. In one class, 73/88 (85%) who had been immunized by skilled personnel at 0, 1 and 6 months, had protective concentrations (greater than or equal to 10 mIU ml-1) of anti-HBs at 20 months after the first dose. Twelve (92%) out of 13 students who received only two doses at 0 and 1 months also had protective concentrations at month 20. At month 27, 11/16 (69%) with antibody less than or equal to 10 mIU ml-1 responded to a fourth dose of 2 micrograms i.d. with protective concentrations of anti-HBs. In the second class, after three doses of vaccine at 0, 1, and 6 months, protective concentrations of anti-HBs were present in 90/93 (97%) at 14 months and in 71/80 (89%) at 25 months. In those who received only two doses, protective concentrations were found in 24/31 (74%) at 14 months and 9/16 (56%) at 25 months. After a booster dose of 2 micrograms i.d. at month 25, anti-HBs concentrations rose from a geometric mean of 78 to 1198 mIU ml-1 in 60 subjects previously immunized with three doses and from 18 to 1054 mIU ml-1 in 16 students previously immunized with only two doses. Overall, 73/76 (96%) of students in the second group had protective concentrations of antibody after the booster dose.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1531719     DOI: 10.1016/0264-410x(92)90416-h

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  3 in total

1.  Preclinical evaluation of microneedle technology for intradermal delivery of influenza vaccines.

Authors:  Jason B Alarcon; Andrea Waterston Hartley; Noel G Harvey; John A Mikszta
Journal:  Clin Vaccine Immunol       Date:  2007-02-28

Review 2.  Intradermal vaccination for infants and children.

Authors:  Akihiko Saitoh; Yuta Aizawa
Journal:  Hum Vaccin Immunother       Date:  2016-05-02       Impact factor: 3.452

3.  Protective immunity in mice achieved with dry powder formulation and alternative delivery of plague F1-V vaccine.

Authors:  Joanne Huang; Ajit J D'Souza; Jason B Alarcon; John A Mikszta; Brandi M Ford; Matthew S Ferriter; Michelle Evans; Todd Stewart; Kei Amemiya; Robert G Ulrich; Vincent J Sullivan
Journal:  Clin Vaccine Immunol       Date:  2009-03-04
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.